Merck & Co (MSD) has initiated the randomised MOBILIZE-1 Phase III trial to assess the immunogenicity, efficacy, and safety ...

Merck is establishing a program of clinical trials for V181, including conducting trials globally, in places where dengue is ...

Merck initiates MOBILIZE-1 phase 3 study evaluating dengue vaccine candidate, V181: Rahway, New Jersey Friday, June 13, 2025, 11:00 Hrs [IST] Merck, known as MSD outside of the Un ...

While Takeda's Qdenga (TAK-003) shot is approved as a two-dose regimen to protect people from the disease in dozens of ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the initiation of the MOBILIZE-1 ...

Merck & Co Inc (NYSE:MRK) has begun a Phase 3 clinical trial to test its experimental dengue vaccine in a pediatric ...